Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
about
TB vaccine development and the End TB Strategy: importance and current status.Tuberculosis vaccine types and timingsTCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection.Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogensRv2299c, a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice.Dual Immunization with SseB/Flagellin Provides Enhanced Protection against Salmonella Infection Mediated by Circulating Memory Cells.Towards new TB vaccines: What are the challenges?IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune ResponsesIdentification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis
P2860
Q26748621-AD10B54E-718A-4069-BEAA-4910DB7F386CQ26862762-14205EF4-C0B8-4F59-A661-72B010009BD7Q33605976-30F3DB9F-4FDE-4FC8-9A33-D28C82223C90Q36303844-75706935-54F7-4AC5-840A-5C55732C3062Q36500269-3BF4A10B-DFE8-44EF-BF40-7EFD9ECA9084Q37746200-2842277E-0A7C-44CD-8A35-8B242B85CF39Q38678152-EC45A4CE-C6DB-437A-A048-6AEB96D8DD8FQ38767468-621998AA-6905-42EB-B00E-BD1D99E54729Q40476014-8BF4F234-1972-4263-AA93-2B8BE2193001Q47221323-DABFF75B-C966-42CC-91FC-82827F330CB8Q52584422-26878656-FEE1-4CA3-9C2C-D774E56CA1CCQ55691134-369D3396-0288-4BF3-B2F5-A9C1B58C4DA4Q56944933-DE4C74B1-875D-4328-AB1C-0931BB0ECFB7Q56976379-66F3EA67-1765-493C-B1CF-0ECEE640872A
P2860
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@ast
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@en
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@nl
type
label
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@ast
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@en
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@nl
prefLabel
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@ast
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@en
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.
@en
P2093
David Argilla
Elyse A Beebe
Gregory C Ireton
Po-Wei D Huang
Rhea N Coler
Valerie A Reese
P2860
P304
P356
10.4049/JIMMUNOL.1401103
P407
P577
2014-08-01T00:00:00Z